United Therapeutics Corp (NAS:UTHR)
$ 360.87 -2.78 (-0.76%) Market Cap: 16.11 Bil Enterprise Value: 13.18 Bil PE Ratio: 15.85 PB Ratio: 2.64 GF Score: 86/100

United Therapeutics Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 03:50PM GMT
Release Date Price: $168.03 (+1.79%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan, and we're continuing the health care conference this morning with United Therapeutics. I'm joined by the company's CEO, Martine Rothblatt. And unlike in normal year where I'd send you down to the Yorkshire room for Q&A, this is going to move seamlessly into a Q&A after her presentation. If you want to participate in Q&A, there's a ask a question button on your screen. Just click on that. It sends the questions to a portal so that I can read them to management. But in the meantime, we can get started.

Let me pass it over to Dewey Steadman from IR, first.

Dewey Steadman
United Therapeutics Corporation - Head of IR

Hey, good morning. Our remarks today may include forward-looking information about our business. And please see our SEC filings for risks and uncertainties that could cause actual results to differ. Also, Martine's presentation today is available as a PDF

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot